Financial Data and Key Metrics Changes - Old National Bancorp reported GAAP earnings per share of $0.46 for Q3 2025, with adjusted earnings per share of $0.59, reflecting an 11% increase from the prior quarter and a 28% increase year over year [7][12] - The company achieved a 20% return on average tangible common equity and a 1.3% return on assets, with an efficiency ratio below 50% [3][5] - The CET1 ratio increased by 28 basis points to over 11%, and tangible book value per share grew by 4% from Q2 and 10% year over year [7][15] Business Line Data and Key Metrics Changes - Total loans grew 3.1% annualized from the previous quarter, with production up 20% from the prior quarter [8][9] - Adjusted non-interest income was $130 million for the quarter, exceeding guidance, driven by strong performance in capital markets [12][18] - Adjusted non-interest expenses were $376 million, reflecting a full quarter impact of Bremer operations, with a low efficiency ratio of 48% [13][19] Market Data and Key Metrics Changes - Total deposits increased by 4.8% annualized, with core deposits (excluding brokered) increasing by 5.8% annualized [10][11] - Non-interest bearing deposits remained at 24% of core deposits, and brokered deposits decreased modestly [10][11] - The company achieved an approximate 85% beta on its exception price book spot rate in conjunction with the Fed rate cut in September [11] Company Strategy and Development Direction - The company is focused on organic growth and returning capital to shareholders, emphasizing that the best acquisition is itself [5][25] - Management is strategically recruiting top-tier talent and investing in future growth opportunities while enhancing efficiency [4][6] - The company aims to leverage its leading market position and capitalize on market disruptions [4][5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the credit outlook, noting a decline in criticized and classified loans and stable credit metrics [15][19] - The company anticipates continued success in executing its deposit strategy and expects to meet or exceed industry growth in 2025 [18][19] - Management highlighted that the systems conversion for the Bremer Bank partnership was successful, with positive client sentiment and operational efficiency [36][38] Other Important Information - The company repurchased 1.1 million shares late in the quarter, reflecting confidence in capital levels and the trajectory of the business [16][102] - The full run-rate cost savings from the Bremer acquisition are expected to materialize in Q1 of the following year [95][96] Q&A Session Summary Question: What drove the reduction in NII expectations for the fourth quarter? - Management indicated that the reduction from $590 million to $585 million is minor relative to the overall balance sheet size and reflects stable dynamics [22][23] Question: What are the preferred uses for capital moving forward? - Management emphasized organic growth as the primary focus, with opportunistic buybacks based on capital generation [24][25] Question: How did the systems conversion go? - Management reported that the systems conversion was the best to date, with high client satisfaction and minimal issues [36][38] Question: What is the outlook for loan growth from Bremer? - Management expects consolidated loan growth to align with overall company growth, with no significant swings anticipated [70][73] Question: How does the company view the credit environment? - Management described the credit outlook as stable to improving, with a focus on active portfolio management [97][99]

Core Points - MGIC Investment Corporation plans to release its third quarter 2025 financial results on October 29, 2025, after market close [1] - A conference call/webcast is scheduled for October 30, 2025, at 10:00 a.m. Eastern Time to discuss the quarterly results [1][2] - The company encourages interested individuals to register for the call and join at least 10 minutes early [2] Company Overview - MGIC, the principal subsidiary of MGIC Investment Corporation, provides private mortgage insurance to lenders across the United States, facilitating affordable low-down-payment mortgages [3] - The company aims to help families achieve homeownership sooner through its services [3] Investor Communication - MGIC Investment Corporation releases important information via its corporate website and encourages investors to enroll for automatic email alerts and RSS feeds regarding new postings [4] - The company intends to continue this practice for future disclosures [4]

Funding Closed and Farmout Agreement September 2025 CFO David M. Smith General Counsel Eon Resources Inc. NYSE-AM:EONR https://www.EON-R.com/ NYSEAM:EONR NYSEAM:EONR Presenters Dante V. Caravaggio CEO Mitchell B. Trotter Jesse J. Allen VP of Operations 2 NYSEAM:EONR Company Overview Leasehold Acres ~ 20,000 acres (two fields) Grayburg-Jackson Oil Field (Eddy County) & South Justis Field (Lea County) Fields Wells (Producing + Injection) ~ 750 wells across both fields Current Oil Production Over 1,000 barrels ...

Group 1 - The article does not provide any specific information or data regarding companies or industries [1]

Financial Data and Key Metrics Changes - The company reported a strong second quarter in 2025, driven by the incretin teams on Mounjaro and Zepbound, particularly in the U.S. and internationally [2] - The U.S. opportunity in type 2 diabetes is significant, with a reported HbA1c reduction of 1.8 and weight loss of 10.5 in the obese population with type 2 diabetes [6][7] - The company anticipates a gradual growth in the second half of the year, contrasting with the strong performance in Q2 [16] Business Line Data and Key Metrics Changes - The composition of the U.S. business is shifting, with 25% of incretin performance coming from type 2 diabetes and 75% from chronic weight management [10] - The company launched Mounjaro in Brazil, Mexico, India, and China, with a significant portion of Q2 sales attributed to chronic weight management [15] - The company expects to see a gradual growth in the second half of the year due to fewer major launches compared to Q2 [16] Market Data and Key Metrics Changes - The U.S. market for oral type 2 diabetes medications is substantial, with approximately 4 million patients on orals each month [6] - The company noted that the majority of its business outside the U.S. is cash-based, with limited reimbursement for chronic weight management [10] - The company is negotiating for type 2 diabetes reimbursement in several international markets, which is expected to take time [10] Company Strategy and Development Direction - The company is focused on launching a rich pipeline of products over the remaining part of the decade, with several launches planned for the second half of the year [2] - The management emphasized the importance of outcome data to gain access and reimbursement for chronic weight management, both in the U.S. and internationally [14] - The company is optimistic about the future of its oncology and neuroscience portfolios, with several promising assets in development [41][42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the guidance for 2025, citing a lack of supply constraints that affected previous years [26] - The company is optimistic about the potential for growth in the U.S. diabetes market and is working to improve employer opt-in rates for chronic weight management [27][28] - Management acknowledged the challenges of gaining reimbursement for chronic weight management outside the U.S. but remains committed to differentiating its products [36] Other Important Information - The company is facing legal challenges related to compounding lawsuits but is actively pursuing various strategies to address these issues [45] - The impact of the Inflation Reduction Act (IRA) on the company's business is still uncertain, with management anticipating some effects on Medicare and Medicaid [47] Q&A Session Summary Question: How is the product profile of Orforglipron fitting in the marketplace? - Management indicated that Orforglipron has a strong safety and tolerability profile, with appealing data for both HbA1c reduction and weight loss [3][4] Question: What are the expectations for the U.S. market penetration with R4? - Management believes R4 will be a global player, with significant opportunities in the U.S. market for type 2 diabetes [6][12] Question: How does the company view the impact of the CVS change on Zepbound? - Management noted that the CVS change affected approximately 200,000 patients, but they have seen a return to strong growth in market share for Zepbound [22][23] Question: What is the outlook for the company's guidance compared to last year? - Management stated that the guidance process remains consistent, with more certainty in 2025 compared to the unpredictable conditions of 2024 [25][26] Question: How is the company addressing the access situation for 2026? - Management reported that they have made progress in employer opt-in rates and are in discussions for broader coverage in Medicare [27][28] Question: What is the competitive landscape in international markets? - Management acknowledged increased competition but emphasized their differentiation strategy and premium pricing for Mounjaro [33][36] Question: What are the exciting opportunities in the non-incretin side of the business? - Management highlighted the oncology franchise as particularly promising, with several assets in development that could drive future growth [41][42]

Financial Data and Key Metrics Changes - Q3 consolidated revenues increased by 5.7% year over year, reaching $1,060 million, with organic growth of 2% [7][26] - Non-GAAP earnings per share (EPS) grew by 15% to $1.1, with free cash flow reported at $165 million [7][28] - Gross margin improved by 70 basis points to 67.3%, driven by efficiency gains and favorable foreign exchange [26] Business Line Data and Key Metrics Changes - CooperVision reported revenues of $718 million, reflecting a 6.3% increase and 2.4% organic growth, although results were below expectations due to declines in Clarity and e-commerce weakness in Asia Pacific [8][10] - CooperSurgical posted revenues of $342 million, up 4.5% or 2% organically, with fertility revenues growing 6% [20][21] Market Data and Key Metrics Changes - EMEA region grew by 14% or 6% organically, becoming CooperVision's largest revenue region globally [10] - The Americas grew by 2% or 3% organically, while Asia Pacific saw a 1% increase but a 5% organic decline [10] Company Strategy and Development Direction - The company aims to leverage the strong momentum of MyDay and upcoming product launches to outpace the contact lens market and gain market share [24] - Focus on operational excellence and disciplined cost management to support sustainable revenue growth [7][30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged headwinds from Clarity and e-commerce challenges in Asia Pacific but expressed confidence in the long-term outlook for both CooperVision and CooperSurgical [20][24] - The company expects to generate approximately $2 billion in free cash flow over the next three fiscal years, with a focus on debt reduction and share repurchases [30][31] Other Important Information - The company is implementing mitigation strategies for tariffs, expecting a $24 million lower impact than previously anticipated [30] - Significant progress has been made in IT upgrades and organizational efficiency initiatives [30][71] Q&A Session Summary Question: How does the core CVI portfolio compare to the market for fiscal 2026? - Management indicated that the core portfolio is expected to be at least in line with the market, with additional growth from MiSight [37][38] Question: Why is MyDay's success impacting Clarity? - Management noted that in some markets, Clarity and MyDay were viewed similarly, leading to a shift in customer preference towards MyDay [41][42] Question: What is the outlook for the contact lens market? - Management acknowledged a slowdown in market growth but remains optimistic about future performance driven by silicone hydrogel lenses and multifocal products [19][50] Question: What are the expectations for the fertility market? - Management expects a rebound in the fertility market as clinics begin investing again, despite near-term pressures [20][110] Question: What is the situation with PARAGARD? - Management reported declining volumes for PARAGARD but offsetting revenue through pricing strategies [114][116]

Financial Data and Key Metrics Changes - Consolidated net sales for Q3 were $2 billion, with adjusted EBITDA at $397 million, reflecting a 2% increase in sales driven by avian influenza pricing and volume growth in cold chain businesses, partially offset by lower pet food and cereal volumes [17][19] - Adjusted EBITDA guidance for the fiscal year was increased to a range of $1.5 billion to $1.52 billion, suggesting Q4 will be approximately flat to Q3 [22] Business Line Data and Key Metrics Changes - Post Consumer Brands (PCB) net sales decreased by 9%, with cereal volumes down 6% and pet volumes down 13% [17][18] - Foodservice net sales increased by 19%, with volumes up 7%, driven by avian influenza pricing and improved customer foot traffic [19] - Refrigerated Retail net sales increased by 9%, with volumes up 1%, benefiting from the timing of Easter [20] Market Data and Key Metrics Changes - Cereal category volumes were down 4.1% year over year, with the branded portfolio declining by 4.9% [12] - Pet volume consumption decreased by 3.7% year over year, while the category remained flat [12] - Weetabix saw a 2.4% increase in consumption volumes, contrasting with a 1.8% decline in the category [14] Company Strategy and Development Direction - The company is focusing on cost optimization and targeted investments to drive volume growth despite a challenging macro environment [15] - The acquisition of Eighth Avenue is expected to create synergies within nut butter and granola, with integration planned for FY 2026 [7] - The company remains open to M&A opportunities while balancing share buybacks, having repurchased 8% of the company fiscal year to date [8][43] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the overall state of the portfolio, despite challenges from tariffs and regulatory changes [9] - The foodservice business is expected to normalize by the end of Q4, with a projected adjusted EBITDA run rate of approximately $115 million [14] - Management acknowledged the need for a longer recovery timeline for the Nutrish brand due to larger-than-anticipated volume challenges [12] Other Important Information - The company is experiencing a transition in its pet portfolio, with plans to address consumption trends and optimize costs [11] - A severance charge of $5 million was taken to align the workforce with a smaller cereal footprint [19] Q&A Session Summary Question: Insights on fiscal 2026 guidance - Management indicated that they are still in the planning process for fiscal 2026 and acknowledged various factors that could impact performance, including foodservice normalization and contributions from Eighth Avenue [25][28] Question: Cereal category performance - Management noted that private label underperformance in the cereal category is somewhat of a mystery, possibly due to pricing dynamics [29][30] Question: Foodservice pricing recovery - Management clarified that pricing increases in foodservice were driven by recovering costs from Q2 and elevated egg markets [34][35] Question: M&A appetite and market challenges - Management expressed a cautious but open-minded approach to M&A opportunities, noting current market uncertainties and low multiples [41][44] Question: Eighth Avenue acquisition impact - Management confirmed no material changes to the expected contribution from Eighth Avenue for the fiscal year and indicated a path to improvement for next year [68] Question: Portfolio adjustments in Pet - Management highlighted opportunities for portfolio changes but emphasized the need to stabilize the Nutrish brand before making significant adjustments [78] Question: Input costs and product reformulations - Management plans to take a pragmatic approach to product reformulations and innovation in response to regulatory changes [61][63]

Financial Performance - Q3 FY25 - Sales increased by $62.7 million, a 26.9% increase, reaching $296.3 million compared to $233.6 million in Q3'24[13] - Adjusted EBIT increased by $17.5 million, a 38.6% increase, reaching $62.7 million compared to $45.2 million in Q3'24[13] - Adjusted EPS increased by 25%, reaching $1.60 compared to $1.28 in Q3'24[12] - Record ending backlog of $1.17 billion, a 75% increase from September 30, 2024[14] Segment Performance - A&D - Entered Orders increased by $492.3 million, a 546.5% increase, reaching $582.4 million compared to $90.1 million in Q3'24[19] - Sales increased by $49.1 million, a 56.3% increase, reaching $136.3 million compared to $87.2 million in Q3'24[19] - Adjusted EBIT increased by $19.1 million, a 94.3% increase, reaching $39.3 million compared to $20.2 million in Q3'24[19] Segment Performance - USG - Entered Orders increased by $5.5 million, a 5.5% increase, reaching $105.5 million compared to $100.0 million in Q3'24[25] - Sales increased by $2.1 million, a 2.3% increase, reaching $92.4 million compared to $90.3 million in Q3'24[25] - Adjusted EBIT decreased by $0.4 million, a -2.0% decrease, reaching $21.8 million compared to $22.2 million in Q3'24[25] Segment Performance - Test - Sales increased by $11.6 million, a 20.7% increase, reaching $67.7 million compared to $56.1 million in Q3'24[30] - Adjusted EBIT increased by $1.4 million, a 15.4% increase, reaching $10.7 million compared to $9.3 million in Q3'24[30] - Entered Orders decreased by $3.6 million, a -5.7% decrease, reaching $61.2 million compared to $64.8 million in Q3'24[30] Financial Performance - YTD Q3 FY25 - Sales increased by $97.1 million, a 15.0% increase, reaching $742.7 million compared to $645.6 million in Q3 YTD '24[38] - Adjusted EBIT increased by $30.7 million, a 28.6% increase, reaching $138.0 million compared to $107.3 million in Q3 YTD '24[38] - Adjusted EPS increased by 24.1%, reaching $3.71 compared to $2.99 in Q3 YTD '24[38] FY25 Guidance - Full year revenue from Continuing Operations is expected to be $1.075 billion - $1.105 billion[52] - Full Year Adjusted EPS from Continuing Operations is now expected to be in the range of $5.75 - $5.90, a 21% - 24% growth over FY'24[52] - Q4 Adjusted EPS from Continuing Operations is expected to be in the range of $2.04 - $2.19, a 14% - 22% growth over Q4'24[51]

Financial Performance & Unit Repurchase - NGL Total EBITDA by segment is $155.33 million[2] - Water Solutions segment accounts for 92% of NGL's total EBITDA, equivalent to $142.87 million[2] - Crude Oil Logistics segment accounts for 6% of NGL's total EBITDA, equivalent to $9.583 million[2,32] - Liquids Logistics segment accounts for 2% of NGL's total EBITDA, equivalent to $2.87 million[2,32] - NGL repurchased 70,000 Class D preferred units during Q1 2025, representing approximately 12% of the outstanding units[3] Water Solutions Business - NGL Water Solutions has transformed into the largest integrated water disposal system in the Delaware Basin[4] - NGL owns and operates over 800 miles of large diameter produced water pipelines in the Northern Delaware Basin[7,29] - NGL's Delaware Basin water disposal facilities have a permitted capacity of approximately 5,100,000 barrels per day[7] - In FY2025, NGL sold 42.4 million barrels of recycled water[29] - Approximately 90% of produced and flowback water was received via pipeline during FY2025[29] Market Data - Market Capitalization is $1.39 billion[36] - Enterprise Value is $4.31 billion[36]

Financial Data and Key Metrics Changes - For Q2 2025, the company generated GAAP net investment income of $0.34 per share and core net investment income of $0.35 per share, which excludes estimated excise taxes [6] - Net asset value per share decreased by $0.04 during the quarter due to a reduction in spillover income [6] - The investment portfolio at fair value was $985.9 million, slightly down from $991 million in Q1 2025 [7] Business Line Data and Key Metrics Changes - The company invested $15.4 million in three new portfolio companies during the quarter and had $7.4 million in other investment activity at par [7] - Two full repayments totaled $21.7 million, with an additional $10.4 million of other repayments, all at par [7] - 98% of loans were secured, and 91% were priced at floating rates [8] Market Data and Key Metrics Changes - The company ended the quarter with loans to five portfolio companies on nonaccrual, comprising 6.8% of total cost and 3.8% of fair value, representing a decrease from the prior quarter [9] - The average loan per company was $9.2 million, with the largest overall investment at $21.2 million [8] Company Strategy and Development Direction - The company expects to see more equity realizations in the second half of the year, estimating $12 million in proceeds and approximately $10 million in gains [11] - The company plans to continue funding qualifying portfolio company investments through new leverage under the SBIC III license [9] Management's Comments on Operating Environment and Future Outlook - Management noted a meaningful pickup in investment activity and M&A activity, indicating a busy second half of the year [10] - The company anticipates being able to grow the portfolio despite expected repayments, with a robust pipeline of opportunities [30][41] Other Important Information - The company has paid $306 million in dividends since its IPO, representing $17.35 per share to an investor in the IPO [6] - The company has received a green light letter from the Small Business Administration for SBIC III, which is an important step in the process [9] Q&A Session Summary Question: How much spillover is there left over and what's the strategy in terms of increasing leverage to cover the dividend? - The company has just under $45 million of spillover to work off through the dividend, expecting it to be about $38 million next year [17] - Current leverage is about 0.9 on a regulatory test and total leverage for GAAP is about 1.7 times, with a target leverage of about one to one [19] Question: How is the pipeline looking for the remainder of the year and where are the opportunities? - The company has seen a significant increase in M&A activity and expects to continue growing the portfolio with a robust pipeline of actionable opportunities [28][30] Question: Any insight into potential resolutions or progress with the current non-accrual list? - The company is working through the non-accruals, all backed by private equity firms, and had no new non-accruals this quarter [31] Question: What is the level of confidence on realizing potential equity realizations this year? - The company has a high likelihood of realizing the forecasted equity realizations as the businesses are actively marketed and well-performing [36] Question: How much of the portfolio rated three or lower is the company seriously nervous about? - The company expects to receive all principal and associated income from the portfolio rated three or lower, indicating a positive outlook [39]